New Macular Degeneration Drug BEOVU now available at Michigan Retina-Vitreous Institute
Drug-maker Novartis announced on October 8, 2019 that the U.S. Food and Drug Administration (FDA) approved the new drug application for brolucizumab ophthalmic solution (trade name BEOVU), a new product for treatment of neovascular or “wet” age-related macular degeneration (nAMD). About neovascular age-related macular degeneration (nAMD or “wet” AMD) nAMD or “wet” age-related macular degeneration …